Doximity entered this earnings week as a quietly discounted healthcare platform with a P/E below many digital health peers. The stock is no longer quiet. Shares surged about 33% in the first full session after the Q1 2027 report as investors rushed to reprice a business that is pouring money into clinical artificial intelligence while still generating strong profits.

The headline is simple: Doximity delivered roughly $157 million of revenue and a 48% adjusted earnings before interest, taxes, depreciation and amortization margin. The market reaction suggests that the real story is not only about growth, but also about profitability holding up while the company invests in AI.

Love Doximity’s high-margin profitability but want more options that combine strong earnings power with balance sheet strength? Check out the list of solid balance sheet and fundamentals stocks (49 results).

Q1 2027 Earnings Summary

• Revenue, Q1 2027 vs. Q1 2026: US$156.6 million vs. US$145.9 million (up about 7%)
• Net Income, Q1 2027 vs. Q1 2026: US$24.3 million vs. US$53.3 million (down about 54%)
• Basic EPS, Q1 2027 vs. Q1 2026: US$0.13 vs. US$0.28 (down about 53%)
• Adjusted EBITDA Margin, Q1 2027 vs. Q1 2026: 48% vs. 48% (broadly stable)

Prefer clean charts instead of dense earnings tables and PDFs? Get a full visual snapshot of Doximity with a focus on its valuation in the company report for Doximity.

Doximity’s AI Bet Starts To Show Real Traction

The bullish view on Doximity is that clinical AI and workflow tools can deepen its role inside hospitals and pharma while keeping the business highly profitable. Q1 gives some concrete progress against that script. Revenue grew 7% with a 48% adjusted EBITDA margin, which suggests the company is absorbing higher AI spend without a visible breakdown in earnings quality. That matters if you care about the long run monetization of AI rather than just headlines.

On usage milestones, quarterly active workflow prescribers rose 30% and nearly half used AI tools. AI prompt volume climbed 25% quarter on quarter and Scribe users grew roughly 10x in July. Doximity Ask now sits on top of the NOHARM safety benchmark and is approved across more than 150 health systems, with 165 health system clients live on the platform. AI Search has signed programs but no revenue yet, so the commercial proof point is still ahead.

Access the street level revenue and earnings analyst estimates for Doximity to see where the consensus models quietly place Doximity’s next real inflection point.

Doximity Bears Still See Slow Growth And Margin Strain

The core worry around Doximity is that heavier AI spend, tighter ad budgets and regulatory pressure will turn a once high growth platform into a slow, lower margin utility. Q1 does not clear that bar. Revenue grew 7% and management raised full year guidance to roughly 5% growth, which keeps the story firmly in single digit territory. That lines up with concerns about a maturing ad business and cautious pharma and hospital budgets.

EPS fell about 53% year on year to US$0.13 while stock based compensation reached 23% of revenue and non GAAP gross margin slipped to 88%. That is exactly the type of margin compression bears expected from the AI investment ramp. AI Search had no recognized revenue in Q1, so the timing gap between higher compute costs and new income is still unresolved. Safety credentials and usage stats help, but they do not yet disprove the slow growth, lower EPS bear case.

After a 33% single day share price move, compressed margins and rising stock based compensation, it is fair to ask whether Doximity’s AI push is the real risk or just the visible part of a deeper structural shift. Review our independent risk analysis for Doximity which shows 2 important warning signs

Stay Ahead With Doximity Insights

If Doximity’s mix of AI investment, high margins and a sharp share price reaction has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and spot a potential entry that fits your plan. Once you own any stock, use the Portfolio Command Center to cut through noise and surface only the key developments that may matter to your holdings. For a broader view on what other investors are seeing in Doximity and similar stocks, join the Community and compare real world perspectives. This way you can uncover possible catalysts and risks earlier and give yourself a better chance of staying informed about the market.

Seeking Alternatives Beyond Doximity?

Fresh stock ideas can move from under the radar to flying high before most investors react. Use these focused shortlists while it matters and get in early.

• Capture potential breakout income streams by scanning hand picked high yield companies in the 8 dividend fortresses before other investors chase the same payouts.
• Spot early momentum in sectors backed by resilient balance sheets using a curated 78 resilient stocks with low risk scores, which filters for stability while prices are still settling.
• Zero in on companies building the picks and shovels for AI growth with a focused 55 AI infrastructure stocks that highlights those supporting the next wave of demand.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.